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Abstract
Although commonly known as movement disorders, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) 
may present with changes in speech and language alongside or even before motor symptoms. The differential diagnosis of 
these two disorders can be challenging, especially in the early stages. Here we review their impact on speech and language. 
We discuss the neurobiological and clinical-phenomenological overlap of PSP and CBS with each other, and with other 
disorders including non-fluent agrammatic primary progressive aphasia and primary progressive apraxia of speech. Because 
language impairment is often an early and persistent problem in CBS and PSP, there is a need for improved methods for 
language screening in primary and secondary care, and more detailed language assessments in tertiary healthcare settings. 
Improved language assessment may aid differential diagnosis as well as inform clinical management decisions.
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Introduction
Language impairment is increasingly recognised as a feature 
of many neurodegenerative conditions and is not restricted 
to the primary progressive aphasias (PPA). In this review, 
we focus on the speech and language changes caused by 
progressive supranuclear palsy (PSP) and the corticobasal 
syndrome (CBS), and their relationship to PPA. We aim to 
show how the assessment and understanding of language 
deficits can aid the diagnosis of PSP and CBS.
Different regions within the brain’s language network 
are susceptible to different neuropathologies, leading to 
language syndromic profiles which provide clues to the 
underlying pathological process. This is most evident in the 
group of disorders known collectively as PPA. For example, 
tau-positive pathologies with frontal perisylvian degenera-
tion are associated with the non-fluent/agrammatic variant 
of PPA (nfvPPA; previously termed progressive non-fluent 
aphasia, PNFA), and also with apraxia of speech (AOS) 
[1–3]. In contrast, the semantic variant (svPPA) is strongly 
associated with tau-negative TDP43-positive pathology and 
marked anterior temporal atrophy [1, 4, 5], while Alzhei-
mer’s disease (AD) pathology is the principal cause of the 
logopenic variant of PPA (lvPPA) [6]. Such associations 
may also hold for the language impairments arising from 
PSP and CBS.
PSP and CBS are both complex, clinically heterogene-
ous disorders, sometimes described as “Parkinson plus” 
syndromes or “atypical parkinsonism”. In the original 1964 
case series of nine PSP patients [7], cognitive changes were 
described in seven cases, and were often prominent. How-
ever, the disease became defined by its akinetic rigidity and 
oculomotor paresis as primarily a movement disorder. PSP 
was also considered a prototypical “subcortical dementia” 
with cognitive slowing, distinct from the cortical dementias 
[8], although the cognitive profile of PSP is highly sugges-
tive of additional cortical atrophy and pathology [9]. The 
2017 revised clinical diagnostic criteria for PSP redress the 
balance, with cognitive subtypes of PSP supported by neu-
ropathological validation, including “PSP-SL” with speech 
and language impairments [10, 11].
CBS has had a similar nosological journey, with “early 
dementia” as an exclusion in early diagnostic criteria [12]. 
More recently, cognitive changes, including language 
impairment, have been shown to be prominent in CBS as 
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well as PSP [13–16] and may be the presenting symptoms in 
around half of cases [13, 17–19]. The current clinical diag-
nostic criteria for CBS [20] provide for cognitive subtypes, 
including a non-fluent/agrammatic variant of CBS (CBS-
NAV). Here, we review the literature to characterise the lin-
guistic profiles associated with PSP and CBS and suggest 
simple tools for health care professionals to use in assess-
ment of language in suspected cases of both conditions.
It is important to note that most of the evidence to date 
comes from ‘classic’ phenotypes and often with clinical 
diagnosis in the absence of pathological verification. One 
must also distinguish between the clinical syndromes (PSPs 
and CBS) and histopathologically confirmed cases which 
we refer to as PSPd and corticobasal degeneration, CBD. As 
emphasised by Mesulam et al. [21], two additional factors 
interfere with straightforward classifications and summaries 
of evidence: (1) degenerative conditions often change their 
character during disease progression, either bringing new 
features into the picture or changing the prominence of exist-
ing symptoms; (2) some patients manifest patterns of fea-
tures that do not match the syndromes outlined in consensus 
clinical diagnostic criteria.
Clinical and brain imaging features
Progressive supranuclear palsy
PSPs was first described by Steele, Richardson, and Olsze-
wski in 1964 as a progressive neurodegenerative disease 
characterised by vertical supranuclear opthalmoplegia, pseu-
dobulbar palsy, dysarthria, dystonic rigidity of the neck and 
upper trunk, and dementia [7]. Neuropathological investiga-
tion indicated nerve cell loss, neurofibrillary tangles, gliosis, 
and demyelination in the basal ganglia, brain stem, and cer-
ebellum. PSPd is classified as a primary tauopathy [22, 23]. 
MRI investigations show midbrain and frontal atrophy, while 
parietal and temporal regions are relatively spared [24].
Since its first description, a number of clinical variants 
of PSP have been defined based on clinical presentation, 
severity, and neuropathological findings. The term ‘Richard-
son’s syndrome’ (PSP-RS) or Steele–Richardson–Olszewski 
syndrome now refers to the classically described clinical 
presentation. The clinical criteria for PSP proposed by the 
National Institute of Neurological Disorders and Stroke and 
the Society for PSP are highly predictive of PSP pathol-
ogy, i.e., PSPd [25]. However, in a multicentre study of 100 
autopsy-confirmed cases of PSPd, only 24% had originally 
presented as PSP-RS [18], although many others develop 
PSP-RS features with time. New criteria for PSPs have since 
been developed by the Movement Disorder Society-endorsed 
PSP study group (MDS-PSP), to accommodate the vari-
ous clinical presentations associated with PSPs [10]. The 
2017 MDS-PSP criteria identify speech and language as a 
core functional domain, and operationalise the diagnosis of 
the PSP-SL speech/language phenotype (see Table 1 for a 
description).
Corticobasal syndrome
The clinical syndrome of CBS is defined by the combina-
tion of motor deficits (typically progressive asymmetrical 
akinetic rigidity, dystonia, tremor, myoclonus) and deficits 
in higher cortical functions (alien limb, apraxia, cortical sen-
sory change) [26, 27]. This syndrome was associated with 
the specific tau-pathology called corticobasal degeneration 
(CBD, or formerly cortico-basal-ganglionic-degeneration). 
However, pathologically-proven CBD has been associated 
with a range of clinical syndromes including behavioural 
variant frontotemporal dementia (bvFTD), progressive AOS, 
PPA, and PSPs [28, 29]. Likewise, the syndrome of CBS is 
associated with pathologies other than CBD including PSPd, 
frontotemporal lobar degeneration with ubiquitin- and TDP-
43-positive inclusions (FTLD-TDP), AD, Pick’s disease, 
Lewy body disease, as well as mutations in the microtubule-
associated protein tau and progranulin genes [30, 31].
On neuroimaging, CBS typically reveals asymmetric cor-
tical atrophy, particularly in frontal and parietal regions, and 
atrophy of the basal ganglia. However, patterns of atrophy 
may vary according to the underlying pathological process 
and phenotype [32]. In some cases, CBD and PSPd have 
both been associated with greater atrophy of the prefrontal, 
premotor or supplemental motor regions [32], compared to 
temporal regions [28, 33]. These patients tended to present 
with a behavioural or language syndrome partially resem-
bling bvFTD, nfvPPA, or with executive dysfunction. Where 
atrophy is marked in temporoparietal regions in CBS, the 
underlying pathology may be AD [32, 33], while prominent 
frontotemporal atrophy is suggestive of FTLD-TDP pathol-
ogy [32].
Cognitive changes, including impairment in language, 
memory, executive functions, visuospatial abilities and 
social cognition are common in patients with CBS and are 
often the first presenting symptoms [13, 16, 17, 20, 34]. 
Armstrong and colleagues [20] operationalised a non-fluent 
agrammatic clinical phenotype of CBS (CBS-NAV; see 
Table 1). As Table 1 demonstrates, there is substantial over-
lap across the language features of PSP-SL, CBS-NAV, and 
nfvPPA as described in their respective diagnostic criteria.
Speech
Dysarthria is common in PSPs [18, 36–38], including a 
mixed dysarthrophonia with hypokinetic, spastic and, in 
some cases, ataxic components [37–40]. The features of the 
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dysarthria are consistent with the observed neurodegenera-
tion of the midbrain, globus pallidus, striatum, and hypotha-
lamic nucleus [38]. Abnormal characteristics of speech in 
PSPs can include reduced articulatory velocity, prolonged 
speech pauses, inappropriate silences, deficits in vowel 
articulation, harsh voice, stuttering, echolalia, palilalia, and 
hypophonia [37, 38, 40–47].
Dysarthria is also noted in patients with CBS [17, 48–51] 
and is characterised by a disturbance of the temporal and 
prosodic aspects of speech [49]. In comparing CBS and Par-
kinson’s disease (PD), while both groups show dysprosodic 
features such as monopitch and monoloudness, PD patients 
have predominant vocal abnormalities (e.g., harsh or breathy 
voice) whereas CBS patients are more likely to show abnor-
malities in temporal organisation (e.g., slow rate, dysfluency, 
and prolonged duration of phonemes) [49]. Features sug-
gested as indicative of CBD pathology include orobuccal 
apraxia [17, 52, 53] and flat aprosodic speech [15].
Language features
Language impairment was once thought to be uncommon 
in PSPs/PSPd and CBS/CBD [8, 54], but some early studies 
may have overlooked or downplayed language disturbances 
to emphasise the importance of motor features [55]. Addi-
tionally, formal language testing was often not included, or 
described, in early studies. More recent studies suggest that 
language impairment is common in CBS [16, 17, 51, 56] and 
PSPs [57–59], which we summarise here.
Fluency
PSPs and CBS typically result in severely impaired initial 
letter fluency [9, 60–77] and moderate deficits in category 
fluency [9, 41, 60, 64, 67–69, 74, 76–78]. The fact that let-
ter fluency is typically more affected than category fluency 
[9, 64] is consistent with the finding, in functional imaging 
with healthy adults, that letter fluency principally activates 
frontal regions whereas category fluency produces mainly 
temporal-lobe activation [79, 80].
Additionally, the types of words generated are revealing: 
PSPs and CBS patients sometimes, puzzlingly, generate low-
frequency words [81]. For example, ptarmigan, pterodactyl, 
and farinaceous were the only p- and f-words elicited from a 
PSP-RS patient in our clinic. This is distinct from the strong 
bias towards high-frequency words in svPPA and AD [82].
Executive vs. language accounts of fluency impairment
Fluency scores may relate to other measures of language 
ability [83], but it is commonly accepted that fluency per-
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including executive function, initiation, working memory 
and attention [84]. Therefore, without more detailed lan-
guage assessment, it would be unclear whether a fluency 
deficit reflects a breakdown of language per se, other cogni-
tive processes, or both.
Schofield et al. reported impaired letter fluency in 100% 
of 11 autopsy-confirmed PSP-RS patients (PSPd), while 
55% were impaired on a composite score derived from vari-
ous language tests including category fluency [75]. Simi-
larly, confrontation naming was dramatically better than 
letter fluency in a PSPs study by Gerstenecker et al. [85]. 
This suggests that, in at least a subset of patients, fluency 
impairment in PSP is independent from problems in the 
principal aspects of language, although of course language 
deficits, when present, may exacerbate the fluency impair-
ment. Indeed, Sitek et al. [86] reported language impair-
ment (based on assessment of spontaneous speech, naming, 
comprehension, and repetition) in 80% of 20 patients with 
PSP-RS and even hypothesised that this might underlie the 
low Frontal Assessment Battery scores observed in PSPs.
Patients with PSPs and CBS have reduced initiation and 
speed of processing which might in part explain their poor 
fluency, though this would likely have a similar impact on 
letter and category fluency. In a study of over 300 PSPs 
cases [62], the most salient cognitive impairment was on 
the ‘initiation and perseveration’ subscale of the Demen-
tia Rating Scale, although this is a composite score derived 
from tasks which include verbal fluency. While the slowed 
speed of processing in PSPs and CBS patients [57, 73, 87] 
could contribute to their fluency impairment (since these 
tasks are timed), extending the time limit beyond one minute 
rarely improves the number of words elicited in letter flu-
ency from people with PSPs: they appear to dry-up after a 
few words regardless of the time available. Consistent with 
this are findings from Robinson and colleagues [88] showing 
that the majority of words generated over a range of fluency 
tasks by a PSPs patient with frontal dynamic aphasia were 
produced within the first 20–50% of the allotted time.
Neural correlates of fluency impairment
Investigations of neuroanatomical correlates of fluency 
impairment in PSPs seem to implicate the dorsolateral pre-
frontal cortex (DLPFC), concordant with both lesion [89] 
and functional imaging studies [90] associating letter flu-
ency with DLPFC, especially on the left side. Verbal fluency 
(combining letter and category fluency) in PSPs has been 
shown to correlate with a component of the informant-rated 
Katz Adjustment Scale which is purported to correspond to 
DLPFC functioning [91]. Further, impaired letter fluency 
apparently relates to increased neuronal tau deposition in 
the superior frontal gyrus [75], an area associated with 
the executive aspects of the task [92], while a composite 
language score (including category fluency) was related to 
pathology in inferior frontal and perirhinal cortices, areas 
associated with word retrieval [92, 93]. These findings sug-
gest that executive dysfunction underlies the letter fluency 
impairment in PSPs, though they do not definitively estab-
lish whether executive function is vital in fluency tasks gen-
erally or is differentially critical to the initial-letter version.
Neural correlates of fluency impairment in CBS have not 
been extensively investigated. Positron emission tomography 
indicates left frontoparietal hypoperfusion in CBS patients 
with impaired verbal fluency [94], suggesting the presence 
of a broader dysexecutive syndrome. In pathologically-con-
firmed CBD [19], histopathologic abnormalities were most 
prominent in frontal and parietal regions in patients who 
also showed neuropsychological impairment, again consist-
ent with an account involving executive dysfunction.
Naming
Confrontational naming appears to be relatively well pre-
served in PSPs. A mild naming impairment has been 
reported when an extended naming task is used such as the 
full 60-item version of the Boston Naming Test (BNT) [45, 
67, 78, 85, 95, 96], while some studies using shortened nam-
ing tasks have found performance to be normal [69, 97] or 
only mildly impaired [57, 59]. This may suggest that the 
problem relates more to sustained attention than to the pro-
cesses required for object naming per se.
Naming difficulty should not be confused with the more 
common description “word finding difficulty” during con-
versational speech, which is likely to reflect the fluency diffi-
culties outlined above. Maher, Smith and Lees [71] reported 
mild word-finding difficulty in seven out of 25 PSPs patients 
without severe dysphasia or comprehension deficits. Nine 
of the 25 patients completed the Graded Naming Test [98], 
with all but one in the average or superior ranges. Impaired 
word-finding in connected speech was also reported by Kob-
ylecki et al. [99] in 33% of 60 PSPs patients.
Where frank naming errors do occur in PSPs, they are 
often visually related to the target objects [36] and thus may 
be indirectly due to gaze palsy or other visual problems that 
are common in PSPs [36, 58, 100]. There are also a few 
reports of errors at the semantic or lexical retrieval stage [59, 
95], though these could reflect attentional deficits rather than 
a genuine degradation of semantic knowledge.
Confrontational naming is impaired in some patients with 
CBS [17, 19, 56, 101, 102] but often only mildly so [101]. It 
has been suggested that this reflects impaired retrieval rather 
than a semantic deficit, since performance is usually aided 
by phonemic cueing [102, 103], but semantic errors have 
been reported [101]. Naming impairment in CBS has been 
shown to correlate with impaired lexical retrieval (assessed 
using a category fluency task), as well as with impaired 
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visual-spatial functioning [102]. Further, in this study, nam-
ing impairment correlated with volume of the left lateral 
temporal cortex and the left frontal cortex, which, according 
to the authors’ hypotheses, contribute to lexical retrieval and 
verbal working memory, respectively.
The types of errors made during a naming task are rarely 
reported, leaving the basis for these errors in PSPs and/or 
CBS unclear. We suggest that future studies should ana-
lyse and report the types of naming errors in an attempt to 
specify the contribution of lexical, semantic, attentional, and 
visuospatial factors.
Some studies report an intriguingly disproportionate 
impairment for action naming in PSPs and CBS [104–106]. 
For example, in a study of frontotemporal dementia, PSPs, 
and CBS [104], the latter two groups had more difficulty 
with action than object naming which was attributed to 
disruption of frontoparietal-subcortical circuits involved in 
action knowledge and representation. Similarly, Chow et al. 
[105] found that PSPs and CBS patients were impaired on 
sound naming (naming the objects which produce various 
sounds), particularly for manipulable objects (defined as 
objects for which a goal-directed hand movement is required 
to produce the sound; e.g., guitar). Further, performance on 
this task was associated with atrophy of the left pre-motor 
region. This group was not significantly impaired on naming 
using the short form of the BNT (note that all but one of the 
items on this test are non-manipulable objects). These results 
might reflect the role of classical motor networks in speech 
production and language comprehension for actions [107].
Comprehension and semantic association
Systematic investigation suggests that single-word com-
prehension is relatively spared in PSPs [100, 104, 108], 
while sentence comprehension may be mildly impaired [47, 
57, 100, 109], reinforcing the impression in early studies 
[71, 110]. However, five out of six patients investigated 
by Podoll, Schwarz and Noth [36] and more than 50% of 
patients in a study by Catricalà et al. [59] showed impaired 
word as well as sentence comprehension. Comprehension of 
action-verbs may be particularly affected in PSPs, in keeping 
with the deficits in action naming above [106, 111, 112].
While semantic knowledge is relatively preserved in 
PSPs there can be a mild impairment on formal testing. For 
example, on the Sydney Language Battery (SYDBAT) PSPs 
patients were mildly impaired relative to controls, and not 
significantly different from patients with nfvPPA [57]. There 
are also reports of impaired performance on tests of seman-
tic association [57, 59, 95], although there is a significant 
executive component to this test, and furthermore, scan-
ning the test items requires vertical eye movements which 
may disadvantage patients with this disorder. Indeed, many 
assessments of semantic knowledge use word-picture or 
sentence-picture matching tasks on which deficits in visual 
attention or visual scanning may impact performance [100, 
109].
In CBS, single-word comprehension was impaired in 52% 
of patients in Di Stefano et al. [17], but in only two of fifteen 
patients in Huang et al. [51], and no significant difference 
from controls was reported by Cotelli et al. [104]. How-
ever, differences between these studies in (a) the criteria for 
diagnosing CBS (b) the tests used to evaluate single-word 
comprehension (e.g., matching of names to real objects vs. 
pictures), and (c) the methods for classifying impairment 
(e.g., direct comparison to a group of control participants 
vs. normative values) make it difficult to draw generalised 
conclusions.
Patients with a clinical pattern of nfvPPA and pathologi-
cally proven CBD show significant impairment in sentence 
comprehension [113], particularly in later stages of the dis-
ease course [19]. The researchers argued that this deficit 
reflected genuinely impaired understanding of grammati-
cally complex sentences rather than problems of single-word 
knowledge. Further detail was provided by Cotelli et al. 
[114] who reported unimpaired sentence comprehension in 
a CBS group as measured using a sentence-picture match-
ing task, but impaired ability to detect violations of gram-
mar during a sentence judgment task. The interpretation of 
a specific syntactic deficit may, however, be complicated by 
the fact that patients with CBS [101, 115] and pathologi-
cally proven CBD [19] can show impairments on tasks of 
semantic association. The difficulty in judging a sentence as 
ungrammatical might therefore be, in part, semantic.
Sentence production
Agrammatism is uncommon in early PSP-RS, but features 
of nfvPPA or PSP-SL, including agrammatism, have been 
reported in cases of PSPd [21, 116]. Tasks requiring sen-
tence production, such as picture description, can reveal 
other abnormalities, including: perseverations; fewer mor-
phemes, words, and sentences; and fewer novel words and 
sentences in the context of normal syntactic structure [36, 
58, 59, 100]. CBS, on the other hand, can present with syn-
tactic errors, phonological errors, paraphasias, and speech 
apraxia [17, 51, 101] as well as impaired syntactic knowl-
edge [114] and phonological processing [101]. Unfortu-
nately, differences between these studies hinder clear and 
generalisable conclusions, including differences in diagnos-
tic criteria, sample sizes, test materials and threshold values 
for impaired performance.
Repetition
While repetition has not been extensively investigated in 
PSPs, one study reported that single-word repetition in this 
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group was significantly worse than controls, but significantly 
better than a group with nfvPPA [57]. Four patients present-
ing with nfvPPA who later developed clinical features of 
PSP [117] were not significantly impaired on either single-
word or sentence repetition relative to controls. Further, they 
performed significantly better on both repetition tasks than 
a group of patients with nfvPPA without PSP syndrome.
Deficits of word and sentence repetition have been noted 
in some CBS patients [17, 51, 53]. Impaired sentence rep-
etition, which is characteristic of lvPPA, seems to be more 
common in CBS with underlying amyloid pathology [53].
Reading
In PSPs, where tested, reading is described as slow with 
poor pronunciation due to dysarthria [36, 41, 117]. There 
are also reports of difficulties in deciphering words and/or in 
finding the beginning of each new line in a text, suggesting 
that visual scanning deficits are a significant factor in the 
reading difficulties in PSPs [36].
Patients with CBS may be unimpaired on single word 
reading [101], although a minority of patients make regu-
larisation errors [51, 101] (e.g., pronouncing a written word 
like sew as “sue”, in line with more typical spelling-to-sound 
correspondences). One patient in a study by Graham et al. 
[101] who was severely aphasic made errors which were 
characterised as non-word approximations of the target 
(e.g., girl → “dirl”) or visual errors (e.g. loss → “lost”). The 
majority of CBS patients in this study were impaired on 
a task of non-word reading, consistent with their impaired 
performance on other tasks of phonological skills such as 
phoneme blending and segmentation. Larger studies with 
systematic analysis of reading in PSPs and CBS are so far 
lacking.
Writing
Dysgraphia is common in PSPs and CBS [36, 51], and may 
be due to linguistic, cognitive, visual, or motor impairment. 
Writing features noted in PSPs include micrographia, abnor-
mal slanting, omission of letters and words, addition of let-
ters, and omission of diacritic marks in a Polish-language 
group [36, 59, 96, 118, 119]. The micrographia of PSPs 
differs from Parkinson’s disease by the absence of progres-
sive fatigue (reducing letter size). The dysgraphia in PSPs 
may result from visuo-constructional or oculomotor deficits, 
whereby abnormal vertical and horizontal saccades disrupt 
the visual monitoring of writing [36, 118], and may be exac-
erbated by severe limb akinesia.
CBS and autopsy-proven CBD are associated with con-
structional apraxia and impaired handwriting, in keeping 
with the limb apraxia which affects most patients [19, 
34]. Dysgraphia was claimed to be the most common 
language-related abnormality in CBS by Huang et al. [51], 
although its nature was not described and limb apraxia was 
noted in all patients. Nevertheless, errors both in writing 
and oral spelling (the latter used by Graham et al. [101] to 
avoid the impact of motor deficits on handwriting) in CBS 
have included article omissions, letter substitutions and 
omissions, and a mixture of phonologically plausible and 
non-phonologically plausible spelling errors [101, 120–122].
Summary of language deficits
The language impairment in PSP seems largely consistent 
with a “frontal” deficit, possibly linked to executive dysfunc-
tion and impaired initiation. It has certainly been argued that 
executive deficits underlie the verbal fluency impairment in 
PSP [64, 123]. In contrast to the typically more severe deficit 
of category than letter fluency impairment in AD that sug-
gests a breakdown of semantic memory [9, 64], the reverse 
is typical in PSP and could be explained by problems of 
initiation or general executive function. Indeed, patients with 
PSPs show impairments in other tests of ‘frontal function-
ing’ such as planning, orienting attention, and set-shifting 
[59, 67, 124–126]. Consistent with this are reports of an 
“adynamic aphasia” in PSP, characterised by reduced ver-
bal output and cognitive processing speed [13, 57, 108]. In 
a recent study [57], the finding of only mild or borderline 
correlations between tests of language and those of executive 
function led the authors to conclude that language impair-
ment in PSPs is not solely attributable to executive dysfunc-
tion. It is worth noting, however, that the PSPs cohort in 
this study were recruited from a predominantly cognitive 
disorders clinic and may therefore have presented with more 
cognitive and behavioural features than motor features. 
Future research is clearly needed to delineate the nature of 
the language impairment in PSP, including an analysis of 
the types of errors made by patients on language tasks to 
determine whether these can be “explained away” by visual 
or motor difficulties.
While visual and motor problems exacerbate some of the 
language impairments documented in CBS, these patients 
appear to experience a true breakdown of language ability 
[127]. Aphasic syndromes reported in CBS/CBD include a 
surprisingly wide variety: non-fluent aphasia, anomic apha-
sia, fluent aphasia, Broca’s aphasia, mixed aphasia, and AOS 
[17, 19, 28, 34, 55, 128]. These different patterns may be a 
function of the stage at which assessment occurs, or perhaps 
they will be found to relate to the different pathologies which 
may underlie CBS when these are better delineated.
Most of the evidence to date comes from studies of clas-
sic phenotypes. It is becoming clear from the few available 
larger clinicopathological series that phenotypic variation 
is common, including clinical overlap (e.g., PSP-CBS, and 
CBS-PSP) and non-classical phenotypes (e.g., PSP-SL, 
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CBS-NAV) [11, 18, 20, 21, 28, 29], and more such studies 
are clearly needed.
In addition, most studies have been cross-sectional and 
therefore may not adequately characterise the onset and 
evolution of language deficits. Early vs. late language loss 
in PSPs and CBS may turn out to have important clinical 
and pathological implications. From the few longitudinal 
clinicopathologic studies, it seems that patients with PSPd 
who present initially with language impairment (PSP-SL) 
later develop typical motor features (such as falls, abnor-
mal saccades or pursuit, and supranuclear gaze palsy); this 
distinction may help to distinguish PSP-SL from nfvPPA 
[11]. Similarly CBD patients presenting with nfvPPA subse-
quently often show extrapyramidal involvement before death 
[15]. Conversely, in CBS at least, patients presenting with 
typical movement disorders also often develop aphasia or 
behavioural change [129].
Given that language symptoms can vary by stage, differ-
ent clinical tools may be required to elicit and characterise 
language disorders at different stages. For example, patients 
may write answers in early but not late stages; significant 
gaze palsy and visual disturbance in later stages of PSPs may 
limit the usefulness of language tests with visual stimuli; 
and the assessment of aphasia can be complicated by the 
development of dysarthrophonia.
Clinical utility of language assessment 
for PSP and CBS
Speech and language assessment may have utility for the 
differential diagnosis of PSP and CBD, which clearly over-
lap clinically and pathologically with each other and with 
disorders such as AD and PD. Language assessment may 
also aid monitoring and prediction of prognosis. This sec-
tion outlines the differential linguistic features of CBD and 
PSPd, and provides recommendations, based on our review, 




The patterns of linguistic impairment in PSP and CBD 
clearly overlap. Clinicopathological case reports demon-
strate that both PSPd and CBD can present with AOS and/
or nfvPPA [128]. AOS is a motor speech disorder charac-
terised by dysprosodic speech, distorted sound substitutions, 
phonological additions, repetitions and prolongations, and 
decreased articulatory accuracy [116, 128]. Originally 
described in association with post-stroke aetiology [130], 
AOS is increasingly recognised in neurodegenerative 
conditions, including a clinical syndrome of primary pro-
gressive AOS (PPAOS) [131]. PPAOS has been distin-
guished from nfvPPA, which is a language disorder defined 
by agrammatic speech/writing, telegraphic or truncated 
speech, and impaired syntactic comprehension [35]. To 
make matters more complicated, the clinical features of 
apraxia and aphasia often co-occur [128].
Many patients with AOS/nfvPPA go on to develop motor 
symptoms and/or have autopsy-confirmed PSP or CBD 
[132–135]. In other words, AOS or nfvPPA may be pro-
dromes to PSPs or CBS. Whether a case is labelled PPA, 
PPAOS, PSPs or CBS may depend on the stage of disease 
at which a patient is referred and the diagnosis made, or 
the expertise and interest of the clinician in eliciting rel-
evant features [128]. Nevertheless, there may turn out to 
be linguistic features which help to differentiate PSP from 
CBD pathology: while both AOS and nfvPPA occur in CBD, 
PSPd appears to be more commonly associated with AOS 
without nfvPPA [136]; meanwhile, patients who meet the 
MDS-PSP criteria for PSP-SL may be more likely to have 
CBD than PSPd [137].
PSP vs. PD
Idiopathic Parkinson’s disease is associated with mild 
impairment of speech production, including the domains of 
volume (hypophonia), fluency, grammaticality, naming, syn-
tactic complexity, and discourse [138, 139]. However, there 
are discernible differences in linguistic features between PD 
and PSP.
Language impairment is apparent early in the disease 
course in some PSPs patients [66], whereas language or 
global cognitive impairment typically occurs late in PD 
[140]. Letter and category fluency are significantly more 
impaired in PSP relative to PD patients [59, 74, 77, 81, 96, 
140]. Foley et al. [140] compared naming, comprehension, 
and spelling in the two disorders. The PSPs patients were 
significantly more impaired than the PD patients on one 
of two spelling tasks. There were no group differences in 
naming using the 30-item Graded Naming Test [98], but 
significantly impaired naming in PSPs compared to PD was 
reported in another study using the 60-item Boston Naming 
Test [96]. PSPs patients may have significant handwriting 
impairment relative to PD patients, consistent with their 
apraxia and vertical gaze palsy [96].
Catricalà et al. [59] conducted a more detailed investiga-
tion of linguistic features in Italian-speaking PSPs and PD 
patients. The PSPs group were significantly impaired rela-
tive to the PD group on a range of language tasks, includ-
ing naming, single word and sentence comprehension, sen-
tence repetition, reading, semantic association, and in the 
number of orthographic errors during writing, although the 
PD group were significantly older than the PSPs group. In 
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comparing a subset of the PD patients who were matched 
in age to the PSPs patients, sentence repetition and single 
word comprehension were no longer significantly different 
between groups. The researchers also examined linguistic 
features using a connected speech task. Relative to controls, 
PSPs patients showed a lower speech rate, with fewer sen-
tences, words, and information units but a greater number 
of pronouns, and poorer performance on two measures of 
discourse efficiency and effectiveness; PD patients were 
impaired only for discourse efficiency and effectiveness. In 
comparing PSPs and PD, PD patients produced fewer nouns 
and more incomplete sentences, while PSPs patients had a 
lower speech rate, and produced fewer words, sentences and 
information units. The researchers concluded that language 
impairment, particularly lexico-semantic and syntactic 
impairment, is more severe in PSPs than in PD.
Motor speech assessment may also help distinguish PSP 
from PD. PD is characterised by pure hypokinetic dysar-
thria with hypophonic, monotonous speech whereas PSPs 
produces more severe mixed dysarthrophonia [38, 41, 58]. 
Further, dysarthria typically is present earlier and progresses 
more rapidly in PSPs than in PD [58].
CBD vs. AD
CBS can be due to underlying CBD (CBS-CBD) but is also 
commonly caused by AD pathology (CBS-AD). Typical AD 
patients often show language impairment, particularly in cat-
egory fluency, naming, semantic knowledge, and discourse-
level processing, with relatively intact syntactic and phono-
logical abilities [141]. The logopenic variant of PPA, which 
is associated with Alzheimer’s pathology, is characterised 
by particular difficulties with word retrieval and sentence 
repetition [35].
A more challenging problem is to distinguish CBS-CBD 
from CBS-AD. The former is often associated with atro-
phy of frontal regions, whereas cases of the latter more 
often show temporoparietal atrophy [32, 33]. Accordingly, 
CBS-CBD patients may present with frontal features such 
as nfvPPA [52]. Hu et al. [142] recorded AOS in four of 
eleven CBS-CBD patients but in none of five CBS-AD 
patients. This difference, though not statistically significant 
with small numbers, may provide a pointer to phenomena 
for future investigation. Unfortunately, detailed language 
assessment was not reported in this study; but the finding 
of fronto-temporal hypoperfusion in the CBS-CBD patients 
suggests that linguistic impairment might have been detected 
if assessed. CBS-AD, however, may show more severe sen-
tence repetition impairment, consistent with findings localis-
ing damage to more posterior brain regions [17, 33, 53, 142]. 
Further evidence on the distinctions between CBS-CBD and 
CBS-AD will require larger series of pathologically proven 
cases, or the use of robust biomarkers of clinical pathology 
using cerebrospinal fluid analysis or amyloid imaging.
Tools for the assessment of language in PSP and CBS
Brief bedside tests
Two brief bedside language tests which are especially use-
ful for crude diagnostic classification of PSPs and CBS are 
verbal fluency and reading. Letter fluency is significantly 
more impaired in PSPs patients compared to several other 
neurodegenerative disorders including idiopathic PD [74, 
81, 140], multiple system atrophy [74], and AD [64]. Indeed, 
the generation of seven or fewer words in 1 min of a letter 
fluency task accurately distinguishes PSPs from other move-
ment disorders [81, 143]. Reading tasks may also have utility 
in diagnosis of PSPs and CBS: impaired reading of easy, 
regular words is consistent with PSP patients’ difficulties in 
deciphering words [36], while impaired non-word reading 
is consistent with the phonological difficulties seen in CBS 
[101].
Extended in‑clinic assessment
Most of the speech and language tests used in PPA research, 
such as the Western Aphasia Battery [144] and the Boston 
Diagnostic Aphasia Examination [145], were designed for 
post-stroke aphasia and thus should be supplemented with 
language tests developed specifically for progressive apha-
sia, such as the Northwestern Anagram Test (NAT) and the 
Sydney Language Battery (SYDBAT). The NAT can be used 
to assess syntactic abilities in patients who have impaired 
speech production [146], so is suitable for patients with AOS 
or a non-fluent presentation of PSPs or CBS. The SYDBAT 
evaluates naming, word repetition, word comprehension, and 
semantic association [147].
There is a need for a short standardised evaluation of 
progressive aphasia, suitable to apply the clinical diagnos-
tic criteria [148]. A recently developed language screening 
tool for use in neurodegenerative disorders is the Mini 
Linguistic State Examination (MLSE; www.mlsex am.com) 
designed to screen for language impairment and to clas-
sify different varieties of PPA. The MLSE contains sub-
tests which span the most commonly affected linguistic 
components in PPA, and is based on the recommenda-
tions of current diagnostic guidelines [35]. Of note, the 
MLSE incorporates error type classification within its 
scoring system. The MLSE has been developed initially 
in English and Italian but has the potential to be adapted 
for other languages/cultures, which will enable compari-
son of PPA patterns across languages and should provide 
previously unavailable advances in our understanding of 
these conditions. Research centres interested in adapting 
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the MLSE are advised to contact the study team via www.
mlsex am.com. Note that at the time of press, the MLSE is 
undergoing validation testing in English and Italian, but 
will in due course be made freely available for clinical and 
academic research purposes.
Where it is available, more detailed neuropsychologi-
cal assessment can be useful to detect subtle impairments, 
nuance subgrouping, and predict prognosis. It is important 
for a neurological/neuropsychological assessment to evalu-
ate the impact of other factors on performance on language 
tests, including executive function, mood, memory, visual 
problems, and motor abilities. Where motor or visual prob-
lems are detected, assessment should be adapted appropri-
ately, for example using tests which do not rely on visual 
processing (such as orally-presented syntactic comprehen-
sion tests in addition to a sentence-picture matching task). 
Presenting tests at eye-level may also facilitate assessment 
of PSP patients, who lack vertical eye movements [58].
The 2017 MDS-PSP criteria for clinical diagnosis of PSP 
will facilitate the characterisation of the neuropsychologi-
cal and linguistic profile of the variants of PSPs [10]. For 
example, PSP-RS is associated with more severe cortical 
atrophy, particularly in frontal regions, than PSP-parkinson-
ism [149, 150] and this is hypothesised to underlie the more 
pronounced cognitive and executive dysfunction in PSP-
RS. Verbal fluency was more impaired in PSP-RS and PSP-
CBS than in PSP with predominant gait freezing (PSP-PGF) 
[151]. Prefrontal atrophy may be still more severe in PSPs 
with prominent nfvPPA [117]. PSP with predominant fron-
totemporal dysfunction is associated with the behavioural 
and cognitive changes typically seen in bvFTD, which have 
included reports of language impairment in up to 37% of 
patients [66]. PSPd presenting as CBS has been associated 
with progressive aphasia and specifically with nfvPPA [137, 
152]. Additionally, micrographia is noted in patients with 
PSP-PGF [42, 43]. Such speech and language changes could 
be useful for predicting prognosis. For example, slowly pro-
gressing CBS patients were significantly more likely to have 
a motor speech disorder than rapid progressors, and there 
was a trend for more frequent dysgraphia [51].
Conclusion
Although more research is needed to characterise the lin-
guistic profiles of these conditions and their longitudinal 
patterns, there is already evidence to date that language 
assessment can play an important role in the clinical evalu-
ation and management of patients with PSPs and CBS.
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